Good afternoon, everybody, and thank you for joining us here for the March quarterly webinar for Emyria. We have the Chief Operating Officer, Mary-Ann Rennie, and the Executive Chairman, Mr.

Greg Hutchinson, to run us through the presentation, and we'll have some time for questions. Hand it over to Greg to walk through the presentation.

Thank you.

Thanks, Pete. It's been an incredibly exciting time in the psychedelic space over the course of the last 3 years, probably no more exciting a time as over the last month or so with some developments that we're seeing on the world stage.

In addition to presenting some of our quarterly highlights, we thought we might also touch on some of those developments and why they're so important to our company. We saw revenue growth over the course of the quarter of $1.2 million, up from $900,000 in the previous quarter.

We don't expect that revenue will continue to accelerate in a linear fashion necessarily, but as we'll touch on during the course of the presentation today, there are some regulatory catalysts that, when they come to fruition, we think will see more significant growth quarter-on-quarter. We provided an update on our clinical data, durable clinical outcomes in our PTSD program for patients 12 months post-treatment.

76% of those patients achieved a clinically significant improvement, and very importantly, 67% remained in remission. We think that this is an incredibly significant result not just for patients and their families, but for payors for whom the health economic benefits are potentially massive.

We announced that our first Victorian clinic is on track to commence this quarter of the calendar year, and subsequent to the quarter, announced that the New South Wales clinic that we've been hinting at is coming to fruition. In fact, it will become operational in the third quarter of this calendar year at Matilda Nepean Private Hospital.

That's very exciting because we will now have clinics in each of the four most populous states and territories in the country. Of course, we launched our global partnership program in which we're targeting international drug sponsors, and we'll talk a little bit more to that over the course of the presentation.

It was incredibly important that Donald Trump signed an executive order the same day as we launched our global partnership program in which he announced that the US is going to fast-track psychedelic drug research so that patients can gain faster access to psychedelic-assisted therapies. Incredibly exciting quarter for the company and for psychedelic-assisted therapy and psychedelic drug development across the globe.

We'll talk a little bit more about each of these factors and each of these developments now, and I'll hand over to Mary-Ann, who's going to talk about the significance of the global research which is occurring into psychedelic drugs.

Thanks, Greg. Hi, everyone.

Great to be here today. As Greg's spoken about and as we launched last week our global partnership program, there's a huge amount of research taking place globally.

This chart is a bullseye chart, and it effectively shows you the different programs across different drug molecules and the stages of development. As you can see, there's a lot happening in this space and in the sector.

With the executive order taking place, we hope to see further momentum taking this forward. Now, what's really interesting is psychedelic research and drug development is slightly different to traditional drug development in the fact that it's coupled with therapy quite often, or the delivery mechanism is not as easy as a prescription and administration.

It's a combination of the molecule and the therapy, and that's why Emyria is so uniquely positioned to support these companies through our existing clinical network, through the scalable IP that we have developed, and the unique skill set from clinical trial execution all the way to post-approval commercial rollout. You'll see on this slide we've highlighted Science Biosciences.

We're already supporting them, being the lead clinical trials site for their Phase 2b clinical trial that they're running.

Mary-Ann, just before you move on, it's probably pertinent to point out that the Australian Financial Review has run a piece this week on Compass Pathways, and which is a NASDAQ-listed British biotech, now at a $1 billion market cap as a consequence of the executive order that Donald Trump signed last week. Really interesting to see that in that piece they touched on the difficulty in delivering the drug.

Compass has designed a synthetic psilocybin compound, which they call COMP360. That will have profound impacts on patients suffering from mental health illnesses, particularly in depression.

I think they've touched on how difficult this is going to be to deliver at scale. As you pointed out, we are uniquely positioned to be able to assist in that regard.

Very true. Thanks, Greg.

Now, this slide, again speaking about all of the research that's taking place, currently in Australia, the Australia Authorised Prescriber scheme has allowed for the treatment of PTSD and treatment-resistant depression, two indications. What this chart is actually showing is how extensive the indications are that are currently being researched across the globe.

This is promising because there's potential for future indications to be then available for treatment. You can see they span across a whole number of different mental health conditions, neurological disorders, and other disorders.

One notable one is substance use disorder, alcohol use, smoking, opioid use, cocaine use. This chart is really just to show the potential impact that these molecules may have, or these coupled with therapy may have, for those needing treatment.

Now just moving on, Greg has spoken about the regulatory catalysts and the different regulatory navigations that take place. We've got a bit of a traffic light system here.

Now, interestingly, up until last week, Authorised Prescriber time frames were in amber as well. They can take an extended time frame to get them approved, but we were very happy to see that we had six additional approvals come through to support our Perth, our Brisbane, and now our Melbourne clinics.

That's great to see, and we've got well-established partnerships or relationships with the HREC, and we've also got a dedicated AP application teams to manage those timelines. We suspect that they should improve for future applications as well.

Now additionally, for the Authorised Prescriber program, there are current limitations on which disciplines or qualifications of therapists can practice. For example, at the moment, you need a clinical psychologist as one of the two therapists in the room.

We continue to look to broaden those eligibility disciplines, which we understand that the regulatory bodies are looking at, but we are also doing some additional recruitment to ensure that we've got the right staffing mix to support those as we continue to grow our clinics. Then finally, an update on the DVA.

They have a slightly more stringent requirements. Needs to be fourth-line therapy criteria for their members.

We've got direct DVA engagement, and what we're doing is really working with them to ensure that we're implementing their policies appropriately as we gear up to treat our first patient and also the ensuing pipeline of DVA patients after that. Ensuring that we've got the requirements correct.

Further to that, we've just given an Authorised Prescriber status update across the clinics that we're currently running. This is just to show, for example, for Perth last week, that was sitting at four from memory, but it's showing that we're gradually adding Authorised Prescribers to each of our clinics, which is great to see.

Then we've also got additional psychiatrists in process. Those numbers change as we continue to grow, as people are educated and the clinics are coming online and we're getting our applications across the line.

Now moving on to just speak to some of the clinic utilization that we're seeing. This chart's showing dosings, screening As, and screening Bs across our two clinics from January 2025 until the beginning or till the end of April this year.

As you can see, from when the Medibank contract came on board around August last year, the Perth clinic was running, and you can see that dosing, screenings are increasing, and with average utilization across the Perth clinic being 20%, but more recently, 36% over the last 3 months. Now, interestingly, when we overlay Brisbane, which only commenced really truly in January, but it opened last year in November and we started our treatments, but then the Christmas period was obviously in play there.

Interestingly, the Brisbane clinic is following a similar pathway utilization progression, which is great to see, as we continue to educate our referrers, we continue to onboard therapists, and continue to having our additional Authorised Prescribers coming on board. Back to you, Greg.

Thanks, Mariany. Look, we've talked to some of the regulatory catalysts which we anticipate seeing, but from a futuristic perspective, we've talked openly about our desire to grow capacity as quickly as we possibly can, roll out as many beds across the country and make our treatments available to as much of the Australian population as possible as we see some of those regulatory hurdles overcome, or those regulatory catalysts come to fruition.

That will then allow us to optimize utilization of our clinics across the country. We had seen an expansion of funders within our ecosystem, Mariany mentioned Medibank and DVA, and we've also seen workers' compensation insurers start to pay for patients who have a mental health-related workers' compensation claim on an ad hoc basis at the moment, and we expect that that will grow over time.

Some of the very exciting things that we're seeing are these new indications as a possible trajectory for our company. In other words, that we expand beyond treatment for PTSD and treatment-resistant depression into what you might call more mainstream or different mental health illnesses, including, as Mary-Ann said, anxiety, obsessive-compulsive disorders, and other addictive substance abuse disorders.

Of course, very excitingly, we see ourselves now as a global participant in the psychedelic-assisted therapy ecosystem, and the launch of our global partnership program and the introduction of potential new drug development sponsors, new drug development companies across the globe is something that we think we can provide a solution to in terms of the delivery mechanism. Why invest?

I guess the first-mover advantage that we've talked about at length as a country and as a company is incredibly important to us, and we're looking to capitalize on that as quickly as we possibly can. The total addressable market globally is obviously something that we see as being incredibly large and is actually growing with the amount of emphasis on mental health treatments that's taking place across the globe.

One of the things that we've been able to do is operationalize the delivery of psychedelic-assisted therapy at scale, and we see that we have not only first-mover advantage, but a very significant competitive advantage over the rest of the world, having done this at scale over the course of the last 3 years. We've taken a capital-light approach to rolling out clinics.

As we know, we've utilized existing hospital infrastructure across the country to cement our footprint across Australia. We're delivering durable outcomes, and we're generating revenue.

Mary-Ann, we've also got a really strong global board with a lot of expertise.

We sure do, Greg. I can just quickly run you through it.

We've got a good mix of both clinical delivery and drug development expertise that span across Australia and we're very fortunate to have those qualifications and such a strong board.

Fantastic. Pete, open to questions, but it has been an incredibly exciting time for us.

We're obviously growing at pace, but we're seeing the whole psychedelic-assisted therapy environment grow at an amazing pace, with a lot of recognition in the community of the benefits of these treatments.

Thanks, Greg. I think the slide with the future catalysts has some interesting areas where we've got some questions.

The growth capacity nationally, and you said you're growing as fast as you can. I think sometimes some of the questions I've been getting is how fast can that actually materially occur?

Can you give us some color on sort of the pathway towards the opening and treatment commencement of a typical clinic and some of the challenges, and also some of the successful milestones you have in achieving that?

Mary-Ann, I think you'd be better placed to talk to that one.

Sure, happy to. Thanks, Pete.

There are a number of things in play when you establish a clinic. You obviously, once you've identified your partner, you may need to do a small fit-out, typically lightweight, but a fit-out nonetheless.

You get moving onto that quite quickly. At the same time, or in parallel, we commence a recruitment campaign.

They take about 12 weeks to get from recruitment through to training. It's an extensive recruitment campaign because you're typically recruiting 30-plus therapists to support a new clinic.

Then after that, you need to, well, again in parallel, you're looking to establish your Authorised Prescribers, they need to go through their application process and their training and supervision requirements. When you actually open your doors on day one, you don't immediately have the clinic booked.

You're very mindful in how you open it. You need to onboard your therapists.

You need to make sure that your referrer database for that area is well-educated and so they're starting to refer potentially eligible patients through the process. The other thing to be mindful of is that there is a time to delay between screening and treatment.

You come in, you're screened, you have a screening A, then you might go and do some pathology, some additional information they'd be sought from your referring doctor. You then come in for screening B, and if you are deemed eligible by the Authorised Prescriber, you may then need to be tapered off your medication, and that's all prior to you coming in for your active treatment protocol.

Does that answer the question to just give you some good color as to how we actually establish that footprint and pathway? That's why we kind of often talk to that hockey stick kind of graph when we talk about utilization increasing as we continue getting more Authorised Prescribers on board, onboarding our therapists, building our pipeline, educating the referrers, and the like.

No, I think that makes it a bit clearer because some of the questions I get from shareholders is they see that we'll open a clinic and all the revenue comes through, and they forget that there's a process that needs to take place which includes the fit-out, the training, the people, the ramp-up for the patients coming through so that you're comfortable with it.

I think one of the important things to point out, I think, is that we really have a supply-side issue, not a demand-side, which is good because I'd much prefer it that way. We do have a lot of pent-up demand by the time we open a clinic, but it is important to ensure that we have everything operational in place in order to be able to support that demand.

Given the uniqueness of Emyria with the regulatory environment, obviously it's up to the company to make sure that everything is ticked off and approved because you're breaking ground to some degree. Brisbane is commencing with the clinic rollout, and Perth is now established and growing.

Are you finding now that the process is becoming smoother given that we've got quite a bit of experience in this now?

Yes. Definitely, Pete.

Some things are within your control, and then some things you continue to navigate with third parties like the regulatory catalysts and the like, and that's certainly firming up for the country, not just for us as a company, but all of that getting bedded down because those different regulatory bodies are also finalizing, establishing their processes and the like. Most definitely getting easier.

It feels like a bit of a template that we have. We can say, "Right, we've got a new site.

Here we go. These are the activities that we do in parallel," and certainly you learn as you open each new clinic.

Emyria is creating a new medical industry here. Are you finding a good supply of clinicians and people wanting to come on board into this treatment regime that you're building?

There's certainly a lot of excitement in the psychiatric community, a lot of excitement within therapeutic community. We're really not having difficulty finding clinicians.

Obviously, we've got to go through the regulatory hoops, and we take that responsibility very seriously in terms of making sure that we do things absolutely to the letter of the law as far as the regulators are concerned. Yes, we haven't had difficulty in finding clinicians at all.

We just need to make sure that we move through the different regulatory steps appropriately.

I think it's fair to say, sorry, Pete, just to add to that, it's about referrer education. Not all clinicians may want to be a part of it, but for them to get a real understanding of what these treatments look like and, there's ensuring that there's the correct information with an education piece to those referrers.

Greg, moving on to the expanding the funded programs, can you give some colors to the inbound inquiry from potential funders as well as Medibank and the Department of Veterans' Affairs, which have already established those relationships with you?

We're fortunate enough to be able to say that we're having very good conversations with a number of different funding-type bodies, everything from different private health insurers, obviously the DVA is there, but also different workers' compensation insurers. There's a lot of excitement within funding bodies because mental health is a big issue for them from a health economics perspective.

The prospect of being able to have a treatment which is, generally speaking, a one-off treatment program, it's not something that's ongoing—once you've finished the treatment, generally speaking, that's the end of the treatment—and if we continue to see the results that we're getting for patients, will not only have a flow-on effect from, I guess, a societal perspective, but very much from a health economics perspective for those different funding bodies.

Do you think there was a wait-and-see attitude, and now that you've got the results on the board and the clinics are being rolling out, that they're seeing there is less risk involved, and now they can absolutely engage with you?

100%. There's there's definitely been a wait-and-see attitude.

Medibank has been an incredibly good partner of ours, and and we are very appreciative for the support they have demonstrated, and for the, I guess, the leap of faith that they've taken off the back of the clinical trial data that came out of the U.S., of the US, and then the TGA relaxing their restrictions around the use of these drugs and enabling Schedule 8 prescribing to occur. I think that there definitely has been a a wait-and-see approach for a number of different funding bodies.

The the psychedelic industry, if you will, is gaining momentum across the globe, and I think at some point it becomes something that can no longer be ignored by all mainstream funding entities. Thanks, Pete.

We very much appreciate you putting all of this together for us. Those questions were great.

Hopefully, that provides a little bit more color as to how we're performing not only in terms of the metrics that we provide the market on a quarterly basis, but also in terms of how the the strategy is rolling out from in an operational sense as we grow our capacity across the country.

Great. Thanks, Pete.

Thanks, everybody.